Overview
Sermorelin is classified as a ghrh analog peptide. Muscle growth, recovery, sleep, anti-aging.
Natural GH pulse stimulation. Mimics endogenous GHRH to stimulate the pituitary gland's own growth hormone production in a physiologic, pulsatile pattern.
Category
GHRH Analog
Half-Life
0.2h
Route
SubQ
FDA Status
Not Approved
How Does Sermorelin Work?
Natural GH pulse stimulation. Mimics endogenous GHRH to stimulate the pituitary gland's own growth hormone production in a physiologic, pulsatile pattern.
At the molecular level, Sermorelin operates through pathways characteristic of the GHRH Analog class, interacting with target receptors and downstream signaling cascades to produce its observed effects.
Published Research
The following studies are indexed from PubMed and peer-reviewed journals:
[1]Sermorelin increases lean mass in older adults
Vittone et al.: Sermorelin treatment significantly increases lean body mass, improves body composition, and enhances GH/IGF-1 levels in older adults.
Evidence: moderate strong[2]Sermorelin for idiopathic GH deficiency in children (FDA study)
Prakash & Garg: FDA-approved indication sermorelin produces significant and sustained height velocity increases in prepubertal children with GH deficiency.
Evidence: strong[3]Sermorelin restores GH and IGF-1 in aging men
Veldhuis et al. (J. Clin. Endocrinol. Metab.): Demonstrates sermorelin injections effectively restore GH and IGF-1 levels in older men with age-related GH decline.
Evidence: moderate strong[4]Sermorelin gender-specific anabolic responses
Study examining sermorelin's ability to stimulate GH/IGF-1 secretion in men and women, identifying gender-specific anabolic benefits and dosing considerations.
Evidence: moderate[5]Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples.
A study published in Analytical biochemistry investigating the effects and mechanisms.
Evidence: preclinical[6]Growth Hormone-Releasing Hormone Antagonists Increase Radiosensitivity in Non-Small Cell Lung Cancer Cells.
A study published in International journal of molecular sciences investigating the effects and mechanisms.
Evidence: preclinical[7]In-house standards derived from doping peptides: Enzymatic and serum stability and degradation profile of GHRP and GHRH-related peptides.
A study published in Biomedical chromatography : BMC investigating the effects and mechanisms.
Evidence: preclinical[8]A potentially effective drug for patients with recurrent glioma: sermorelin.
A study published in Annals of translational medicine investigating the effects and mechanisms.
Evidence: moderate[9]Growth hormone releasing hormone.
A study published in Clinics in endocrinology and metabolism investigating the effects and mechanisms.
Evidence: preclinical[10]Probing for peptidic drugs (2-10 kDa) in doping control blood samples.
A study published in Analytical science advances investigating the effects and mechanisms.
Evidence: preclinical[11]An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.
A study published in Journal of pharmaceutical and biomedical analysis investigating the effects and mechanisms.
Evidence: preclinical[12]Online large volume sample staking preconcentration and separation of enantiomeric GHRH analogs by capillary electrophoresis.
A study published in Electrophoresis investigating the effects and mechanisms.
Evidence: preclinical[13]Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?
A study published in Clinical interventions in aging investigating the effects and mechanisms.
Evidence: preclinical[14]New agonist- and antagonist-based treatment approaches for advanced prostate cancer.
A study published in The Journal of international medical research investigating the effects and mechanisms.
Evidence: preclinical[15]Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.
A study published in BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy investigating the effects and mechanisms.
Evidence: moderate[16]GHRH agonist MR-409 protects β-cells from streptozotocin-induced diabetes.
A study published in Proceedings of the National Academy of Sciences of the United States of America investigating the effects and mechanisms.
Evidence: preclinical[17]PEGylation of growth hormone-releasing hormone (GRF) analogues.
A study published in Advanced drug delivery reviews investigating the effects and mechanisms.
Evidence: preclinical[18]Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples.
A study published in Journal of mass spectrometry : JMS investigating the effects and mechanisms.
Evidence: preclinical[19]Growth hormone-releasing hormone receptor antagonist MIA-602 attenuates cardiopulmonary injury induced by BSL-2 rVSV-SARS-CoV-2 in hACE2 mice.
A study published in Proceedings of the National Academy of Sciences of the United States of America investigating the effects and mechanisms.
Evidence: preclinical[20]Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.
A study published in American journal of men's health investigating the effects and mechanisms.
Evidence: preclinicalSafety Profile
Very safe; mimics physiology. Previously FDA-approved for GH deficiency diagnosis. Well-tolerated.
| Side Effect | Incidence | Severity |
|---|---|---|
| Injection site reactions | ~8% of users | mild |
| Headache | ~5% of users | mild |
| Flushing | ~6% of users | mild |
| Dizziness | ~3% of users | mild |
Sourcing Sermorelin for Research
If you're looking to source Sermorelin for laboratory research, our vendor directory compares pricing, purity testing, and COA verification from independently vetted suppliers.
* Research vendor — verify your regional regulations before purchase.
Full Research Profile
Sermorelin — dosing, interactions, timelines & more
Comprehensive compound profile with sourcing information, stacking synergies, and outcome timelines.